Table I.
Association between miR-216a-5p expression and the clinicopathological characteristics of the ESCC patients.
| miR-216a-5p expression | ||||
|---|---|---|---|---|
| Characteristics | All cases n (%) | High n (%) | Low n (%) | P-value |
| Total | 83 (100) | 42 (50.6) | 41 (49.4) | |
| Sex | 0.679 | |||
| Male | 59 (71.1) | 29 (49.2) | 30 (50.8) | |
| Female | 24 (28.9) | 13 (54.2) | 11 (45.8) | |
| Age (years) | 0.573 | |||
| <60 | 37 (44.6) | 20 (54.1) | 17 (45.9) | |
| ≥60 | 46 (55.4) | 22 (47.8) | 24 (52.2) | |
| Histology | 0.022 | |||
| Differentiated | 64 (77.1) | 28 (43.8) | 36 (56.3) | |
| Undifferentiated | 19 (22.9) | 14 (73.7) | 5 (26.3) | |
| Tumor depth | 0.006 | |||
| T1-T2 | 40 (48.2) | 14 (35.0) | 26 (65.0) | |
| T3-T4 | 43 (51.8) | 28 (65.1) | 15 (34.9) | |
| Lymph node metastasis | 0.018 | |||
| Negative | 30 (36.1) | 10 (33.3) | 20 (66.7) | |
| Positive | 53 (63.9) | 32 (60.4) | 21 (39.6) | |
| pTNM stage | 0.097 | |||
| I–II | 33 (39.8) | 13 (39.4) | 20 (60.6) | |
| III | 50 (60.2) | 29 (58.0) | 21 (42.0) | |
| Preoperative CEA | 0.588 | |||
| <3.5 | 45 (54.2) | 24 (53.3) | 21 (46.7) | |
| ≥3.5 | 38 (45.8) | 18 (47.4) | 20 (52.6) | |
ESCC, esophageal squamous cell carcinoma; pTNM, pathological tumor/node/metastasis; CEA, carcinoembryonic antigen. P-values in bold print indicate significance.